Leerink Partnrs upgraded shares of Envista (NYSE:NVST – Free Report) from a strong sell rating to a hold rating in a research report released on Thursday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Envista’s FY2024 earnings at $0.70 EPS, Q1 2025 earnings at $0.22 EPS, Q2 2025 earnings at $0.22 EPS, Q3 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.32 EPS and FY2026 earnings at $1.28 EPS.
A number of other equities analysts also recently weighed in on NVST. Stifel Nicolaus boosted their price target on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Needham & Company LLC restated a “hold” rating on shares of Envista in a research note on Thursday. Robert W. Baird boosted their price objective on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday. Bank of America lowered their price objective on Envista from $22.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Finally, Piper Sandler boosted their price objective on Envista from $16.00 to $17.00 and gave the company a “neutral” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $20.71.
View Our Latest Research Report on NVST
Envista Price Performance
Envista (NYSE:NVST – Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.03. The company had revenue of $601.00 million for the quarter, compared to the consensus estimate of $590.34 million. Envista had a negative net margin of 53.42% and a positive return on equity of 3.59%. The firm’s quarterly revenue was down 4.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.43 EPS. On average, equities research analysts forecast that Envista will post 0.69 earnings per share for the current year.
Insider Activity
In related news, CFO Eric D. Hammes acquired 24,532 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average cost of $16.33 per share, for a total transaction of $400,607.56. Following the completion of the transaction, the chief financial officer now owns 24,532 shares in the company, valued at approximately $400,607.56. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.30% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of NVST. Jupiter Asset Management Ltd. bought a new position in shares of Envista in the second quarter worth approximately $69,534,000. Pacer Advisors Inc. boosted its stake in Envista by 11,202.8% in the second quarter. Pacer Advisors Inc. now owns 2,887,426 shares of the company’s stock worth $48,018,000 after buying an additional 2,861,880 shares in the last quarter. Swedbank AB purchased a new stake in Envista in the first quarter worth approximately $53,412,000. Nuance Investments LLC boosted its stake in Envista by 47.2% in the second quarter. Nuance Investments LLC now owns 7,038,313 shares of the company’s stock worth $117,048,000 after buying an additional 2,256,993 shares in the last quarter. Finally, Ariel Investments LLC boosted its stake in Envista by 25.3% in the first quarter. Ariel Investments LLC now owns 8,892,200 shares of the company’s stock worth $190,115,000 after buying an additional 1,795,258 shares in the last quarter.
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Stories
- Five stocks we like better than Envista
- What is a Secondary Public Offering? What Investors Need to Know
- Roblox Stock Set for More Gains After Strong Earnings Report
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Top 3 REIT Picks for 2025: High Yields and Rising Earnings Ahead
- What is a SEC Filing?
- 3 Stocks Well Below 52-Week Highs With Strong Growth Projections
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.